185 related articles for article (PubMed ID: 26175938)
1. Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers.
Zhao Q; Cao J; Wu YC; Liu X; Han J; Huang XC; Jiang LH; Hou XX; Mao WM; Ling ZQ
Am J Cancer Res; 2015; 5(5):1692-705. PubMed ID: 26175938
[TBL] [Abstract][Full Text] [Related]
2. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
[TBL] [Abstract][Full Text] [Related]
3. Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers.
Zhang H; Su Y; Xu F; Kong J; Yu H; Qian B
PLoS One; 2013; 8(11):e81408. PubMed ID: 24282590
[TBL] [Abstract][Full Text] [Related]
4. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
5. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway.
Ma W; Kang Y; Ning L; Tan J; Wang H; Ying Y
Exp Ther Med; 2017 Oct; 14(4):2853-2862. PubMed ID: 28912847
[TBL] [Abstract][Full Text] [Related]
6. Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI.
Ma Y; Pan X; Xu P; Mi Y; Wang W; Wu X; He Q; Liu X; Tang W; An HX
Oncotarget; 2017 Oct; 8(51):88529-88536. PubMed ID: 29179454
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.
Schaefer A; Jung M; Mollenkopf HJ; Wagner I; Stephan C; Jentzmik F; Miller K; Lein M; Kristiansen G; Jung K
Int J Cancer; 2010 Mar; 126(5):1166-76. PubMed ID: 19676045
[TBL] [Abstract][Full Text] [Related]
8. Four plasma miRNAs act as biomarkers for diagnosis and prognosis of non-small cell lung cancer.
Jiang HG; Dai CH; Xu YP; Jiang Q; Xia XB; Shu Y; Li J
Oncol Lett; 2021 Nov; 22(5):792. PubMed ID: 34630703
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E
Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108
[TBL] [Abstract][Full Text] [Related]
10. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer.
Yang X; Zhang Q; Zhang M; Su W; Wang Z; Li Y; Zhang J; Beer DG; Yang S; Chen G
Int J Biol Sci; 2019; 15(8):1712-1722. PubMed ID: 31360113
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14.
Yu F; Liu JB; Wu ZJ; Xie WT; Zhong XJ; Hou LK; Wu W; Lu HM; Jiang XH; Jiang JJ; Cao ZY; Cong GJ; Shi MX; Jia CY; Lu GX; Song YC; Chai L; Lv ZW; Wu CY; Ma YS; Fu D
Cancer Lett; 2018 Jul; 427():74-84. PubMed ID: 29702194
[TBL] [Abstract][Full Text] [Related]
12. Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing.
Hu S; Yuan Y; Song Z; Yan D; Kong X
Cell Physiol Biochem; 2018; 51(6):2509-2522. PubMed ID: 30557872
[TBL] [Abstract][Full Text] [Related]
13. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
14. [Differential expression of serum miRNAs in patients with advanced non-small cell lung cancer treated by gifitinib before and after acquiring drug resistance].
Huang Q; Li D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 43(12):1288-1293. PubMed ID: 30643043
[TBL] [Abstract][Full Text] [Related]
15. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
16. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
18. Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-small Cell Lung Cancer Cell Lines.
Wen C; Xu G; He S; Huang Y; Shi J; Wu L; Zhou H
J Cancer; 2020; 11(13):3816-3826. PubMed ID: 32328186
[No Abstract] [Full Text] [Related]
19. Potential circulating miRNA signature for early detection of NSCLC.
Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion.
Ju L; Han M; Li X; Zhao C
J Cancer; 2017; 8(7):1311-1318. PubMed ID: 28607607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
